English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Pharma & Biotech HealthCare & Pharma
Azelis releases first sustainability report as a testimony of global sustainability efforts
Aug 11, 2020 10:00 HKT
아젤리스, 세계 지속 가능성 노력의 증거로 최초 지속 가능 보고서 발표
Aug 11, 2020 10:00 HKT
Azelis menerbitkan laporan keberlanjutan yang pertama sebagai kesaksian atas usaha-usaha keberlanjutan global
Aug 11, 2020 10:00 HKT
君实生物任命Patricia Keegan博士为首席医学官
Aug 10, 2020 09:56 HKT
以岭药业向上合组织捐赠296万元连花清瘟支持疫情防控
Aug 06, 2020 17:58 HKT
以嶺藥業向上合組織捐贈296萬元連花清瘟支持疫情防控
Aug 06, 2020 17:59 HKT
Milestone for Biowin's Rapid COVID-19 Nucleic Acid Detector
Aug 06, 2020 16:00 HKT
Novotech榮膺全球職場文化權威機構認證的“2020 年最佳職場”稱號
Aug 05, 2020 09:00 HKT
Novotech荣膺全球职场文化权威机构认证的“2020 年最佳职场”称号
Aug 05, 2020 09:00 HKT
전략적 기회: ‘호주에서 수행하는 인간대상 첫 임상시험 및 백신 임상시험’ – 노보텍 (Novotech) 웨비나
Aug 03, 2020 12:00 HKT
노보텍 (Novotech), 세계적 권위의 직장문화 기관으로부터 ‘2020년의 좋은 직장’ 인증 받아
Aug 03, 2020 11:00 HKT
Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials
Jul 31, 2020 08:00 HKT
Captiva Verde Announces Esmeralda Agreement with Mexican Health Care Workers Union for up to USD$142 Million per Year of Annual Product Sales
Jul 28, 2020 07:00 HKT
Impact Biomedical initiates Quantum, a new frontier in Pharmaceutical Development
Jul 31, 2020 15:00 HKT
Epazz DeskFlex Desk and Room Scheduling System Automates Desk Sanitation as Preventive Measure to Combat COVID-19 Infection in the Workplace
Jul 27, 2020 20:00 HKT
Theragen Bio analyzes Korea's largest COVID-19 patient and coronavirus genomic data
Jul 28, 2020 11:00 HKT
MP Biomedicals and A*STAR Co-Develop Rapid Antibody Test Kit for SARS-CoV-2
Jul 24, 2020 17:00 HKT
아방스 클리니컬, 아토사 테라퓨틱스의 두 번째 코로나19 치료제 개발 프로그램인 비강 분무용 치료제 AT-301 임상 연구 계약
Jul 23, 2020 06:00 HKT
Avance Clinical簽約展開Atossa Therapeutics AT-301鼻噴霧劑臨床研究,這是Atossa的第二個新冠肺炎治療開發項目
Jul 23, 2020 06:00 HKT
Avance Clinical签约展开Atossa Therapeutics AT-301鼻喷雾剂临床研究,这是Atossa的第二个新冠肺炎治疗开发项目
Jul 23, 2020 06:00 HKT
Next >>
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: